Chiltern, Charles River Labs Partner on Early-phase Studies

Friday, February 26, 2010 06:54 AM

UK contract research organization (CRO) Chiltern International and preclinical CRO Charles River Laboratories are partnering to conduct and support early-phase radiolabelled studies.

The two companies will collaborate on studies using radiolabelled investigational products out of the CROs’ Europe-based facilities.

Chiltern’s early stage division—Chiltern Early Phase—in Dundee, Scotland, will perform the clinical aspects of the studies. The CRO has a 42-bed clinical pharmacology unit located in a UK National Health Service hospital and medical school. Charles River’s Metabolism and Pharmacokinetics facilty in Edinburgh includes a GMP clean room, licensed for the manufacture of radiolabelled drug products. The close proximity of the two laboratories enables the companies to turn around radioactivity data within 24 hours.

“This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC,” said Chiltern CEO Glenn Kerkhof in a statement. “These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs